{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.0","upperLimit":"39.2","value":"29.5"},{"groupId":"OG001","lowerLimit":"31.9","upperLimit":"57.5","value":"44.4"},{"groupId":"OG002","lowerLimit":"49.1","upperLimit":"79.0","value":"65.1"},{"groupId":"OG003","lowerLimit":"62.2","upperLimit":"81.7","value":"72.7"},{"groupId":"OG004","lowerLimit":"43.5","upperLimit":"76.9","value":"61.1"},{"groupId":"OG005","lowerLimit":"62.5","upperLimit":"92.5","value":"80.7"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.0","upperLimit":"33.1","value":"23.8"},{"groupId":"OG001","lowerLimit":"29.0","upperLimit":"54.4","value":"41.3"},{"groupId":"OG002","lowerLimit":"49.1","upperLimit":"79.0","value":"65.1"},{"groupId":"OG003","lowerLimit":"59.8","upperLimit":"79.7","value":"70.5"},{"groupId":"OG004","lowerLimit":"40.8","upperLimit":"74.5","value":"58.3"},{"groupId":"OG005","lowerLimit":"66.3","upperLimit":"94.5","value":"83.9"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.7","upperLimit":"35.2","value":"25.7"},{"groupId":"OG001","lowerLimit":"33.4","upperLimit":"59.1","value":"46.0"},{"groupId":"OG002","lowerLimit":"46.7","upperLimit":"77.0","value":"62.8"},{"groupId":"OG003","lowerLimit":"58.6","upperLimit":"78.7","value":"69.3"},{"groupId":"OG004","lowerLimit":"40.8","upperLimit":"74.5","value":"58.3"},{"groupId":"OG005","lowerLimit":"58.9","upperLimit":"90.4","value":"77.4"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"88"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"31"}],"units":"Participants"}],"description":"Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings. The last PSA level before the PET scan will be used to stratify the patients","dispersionType":"95% Confidence Interval","groups":[{"description":"PSA \\< 0.5","id":"OG000","title":"PSA<0.5"},{"description":"0.5 ≤ PSA \\< 1.0","id":"OG001","title":"0.5≤PSA<1.0"},{"description":"1.0 ≤ PSA \\< 2.0","id":"OG002","title":"1.0≤PSA<2.0"},{"description":"2.0 ≤ PSA \\< 5.0","id":"OG003","title":"2.0≤PSA<5.0"},{"description":"5.0 ≤ PSA \\< 10.0","id":"OG004","title":"5.0≤PSA<10.0"},{"description":"PSA ≥ 10.0","id":"OG005","title":"PSA≥10.0"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Population (EAP): all patients who received rhPSMA-7.3 (18F) injection followed by a PET/CT scan and for whom sufficient data are available to permit a clear classification following the SoT algorithm, and with baseline PSA available","reportingStatus":"POSTED","timeFrame":"Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan","title":"Patient-level CDR of rhPSMA-7.3 (18F) PET Stratified by PSA Level","type":"SECONDARY","unitOfMeasure":"percentage"}